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Abstract
Over the past three decades, there have been remarkable advances in the treatment of bone and
soft tissue sarcomas. These include the introduction of adjuvant chemotherapy, establishment of
guidelines for adequate surgical margins, and the development of post-excision reconstruction.
There have also been advances in the field of immunotherapy against bone and soft tissue sarcomas,
which, unfortunately, have received less attention. However, lack of progress in chemotherapy-
based treatments for bone and soft tissue sarcomas has reignited interest in immunotherapeutic
approaches. Here we summarize current progress in the immunotherapy of bone and soft tissue
sarcomas including the strategies utilized to identify tumor-associated antigens, and the design of
clinical trials.
Introduction
Bone and soft tissue sarcomas are aggressive malignant
tumors of mesenchymal origin. Despite their low preva-
lence (approximately 1% of all malignant tumors), they
include more than 60 histological subtypes [1,2]. These
subtypes are often associated with unique clinical, prog-
nostic and therapeutic characteristics, leading to difficul-
ties in identifying tumor-specific targets for
immunotherapy and/or other therapeutic modalities. In
contrast, about 10% of newly diagnosed cancers in chil-
dren and adolescents constitute rhabdomyosarcoma,
osteosarcoma, and Ewing sarcoma, highlighting the
weight that these three sarcomas play in pediatric oncol-
ogy [3].
Until 1970, radical excision was the mainstay of treatment
for bone and soft tissue sarcomas. This treatment had
resulted in five-year survival rates of 10–20% in patients
with osteosarcoma and Ewing sarcoma [3]. To improve
such dismal treatment outcomes, efforts have been to fos-
ter two distinct approaches; chemotherapy and immuno-
therapy [4]. Early immunotherapeutic efforts consisted of
tumor extracts or whole tumor cells used for direct autol-
ogous vaccination [5,6] or allogeneic adoptive immuno-
therapy [7,8] in patients with osteosarcoma. These limited
trials suggested an increase in survival rate over surgery
alone. However, the results were not as promising as those
of chemotherapy trials conducted during the same period
[9,10]. Consequently chemotherapy has to date overshad-
owed immunotherapy and neoadjuvant chemotherapy in
combination with surgery has become the standard treat-
ment of osteosarcoma and other pediatric sarcomas [1,3].
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With the technological advancements that lead to the
identification of tumor antigens [11], immunotherapeu-
tic approaches shifted from the usage of crude tumor
extracts or tumor cells to well-characterized antigenic
epitopes. In turn, peptide-based immunotherapy has
allowed a more precise monitoring of immunological
responses to vaccines. While progress has been made pri-
marily in the context of other tumor models such as
melanoma, the relative effectiveness of chemotherapy and
practical difficulties in establishing autologous tumor-
CTL pairs have delayed the interest in tumor antigen iden-
tification out of bone and soft tissue sarcomas [12]. This
attitude has perpetuated until recently, when tumor-spe-
cific fusion genes resulting from chromosomal transloca-
tion were defined in soft tissue sarcomas and later
proposed as candidate antigens [13-15]. In addition, the
authors' group recently identified an osteosarcoma anti-
gen upon establishment of an autologous tumor-CTL pair
[16,17]. These insights have revived the interest to immu-
notherapeutic approaches to bone and soft tissue sarco-
mas based on molecularly defined targets.
Current multimodality treatment protocols including sur-
gery, systemic chemotherapy, and radiotherapy yield five-
year survival rates around 50–70% in patients with high-
grade primary bone and soft tissue sarcomas [1,3]. How-
ever, in the majority of cases, disease presenting with met-
astatic spread or relapses after primary treatment remains
incurable, emphasizing the need for alternative treat-
ments of bone and soft tissue sarcomas.
Immunogenicity of bone and soft tissue sarcoma
Clinical observations
Efficacy of immunotherapy depends primarily on the
inherent immunogenicity of the corresponding tumors.
This can be partly predicted by clinical observations
related to the natural behavior of immune responses of
the host, such as infilitration of T lymphocytes in tumor
tissues and spontaneous tumor regression. Infiltration of
lymphocytes has been seen in a group of inflammatory
soft tissue sarcomas, including inflammatory myofibrob-
lastic tumors [18] and inflammatory malignant fibrous
histiocytomas [19]. However, lymphocytes infiltrating
these tumors are considered to be attracted non-specifi-
cally by cyotokines produced by tumor cells and not by
tumor antigens [20]. Besides inflammatory tumors,
tumor-infiltrating lymphocytes (TIL) were sporadically
observed in soft tissue sarcomas [21-23]. Notably, infiltra-
tion of dendritic cells was also reported in some soft tissue
sarcomas with reactive lymphoid hyperplasia [23]. This
suggests that presentation of tumor antigens may occur in
the regional lymph nodes. To date, prognostic signifi-
cance of lymphocyte- or dendritic cell-infiltration in bone
and soft tissue sarcomas remains to be proved. Also, it
remains unknown whether there are differences in the
immunogenicity of sarcomas between children and
adults.
Spontaneous tumor regression is far more rarely observed.
To our knowledge, there are only two reported cases of
spontaneously regressing osteosarcoma [24,25]. These
observations suggest the relatively low immunogenicity of
bone and soft tissue sarcomas in natural conditions. Com-
pared to malignant melanomas that are co-localized with
Langerhans cells in the dermis and epidermis, there are
few, if any, such immuno-surveillant cells in the deep tis-
sues where sarcomas are developed. Such micro-environ-
mental features may also be attributed to low
immunogenicity of bone and soft tissue sarcomas.
Laboratory observation
The identification of TIL suggests the question of whether
antigen-specific CTL precursors exist in the peripheral
blood of patients with bone and soft tissue sarcomas. CTL
precursors could home to the tumor site or originate from
the presentation of tumor antigens by antigen presenting
cells in tumor draining lymph nodes. Two pioneering
experimental observations [26,27] answered this ques-
tion. Ichino et al. [26] induced CTLs from peripheral
blood mononuclear cells of six patients with osteosar-
coma, which specifically lysed fresh autologous tumor
cells. Subsequently, Slovin et al. [27] developed CTL
clones from one patient with osteosarcoma, and two
patients with malignant fibrous histiocytoma (MFH). We
have also recently established three autologous tumor
cell-CTL pairs from patients with osteosarcoma [16], MFH
of the bone [28], and MFH of the soft tissue, respectively.
In our experience, the main difficulty in identifying sar-
coma-specific antigens comes from the poor adaptability
of sarcoma cells to in vitro culture, while the induction of
tumor-specific CTLs from peripheral blood mononuclear
cells is relatively more reliable thanks for the advance-
ment of techniques for in vitro T cell culture. In addition,
the utilization of tumor-draining lymph node as a source
of antigen-specific lymphocytes and the manipulation of
co-stimulatory pathways such as B7/CD28 and 4-1BB/4-
1BBL have enhanced the success rate of CTL induction
[28,29]. The efficacy in manipulation of costimulatory
pathways to elicit immunological responses in vivo has
been applied to animal models with osteosarcoma [30-
34] and used in clinical trials on patients with malignant
melanoma [35,36].
Another important advancement in the characterization
of natural immune responses to sarcomas has come from
the direct enumeration of tumor antigen-specific T cells in
the circulation of patients with cancer. The introduction
of HLA/peptide tetramer complexes technology [37] has
made it possible to more precisely monitor the presence
and frequency of circulating CTL precursors when theJournal of Translational Medicine 2005, 3:31 http://www.translational-medicine.com/content/3/1/31
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antigenic epitope and its associated HLA alleles is known.
In this technology, soluble HLA/peptide complexes are
assembled and biotinylated in vitro, and then are forced
to form tetrameric arrays by addition of fluorescent-
labeled avidin molecules. The HLA/peptide tetramer com-
plexes bind to a T cell receptor on lymphocytes, which are
visualized by FACS analysis. Using HLA-A24/SYT-SSX
peptide tetramers, we observed an increased frequency of
CTL precursors specific for SYT-SSX-derived antigenic pep-
tides in patients with synovial sarcomas, compared to
those with other sarcomas and healthy donors [38-40]. In
addition, increased in vivo frequency of CTL precursors
recognizing SYT-SSX-derived peptides was significantly
associated with present or past history of distant metas-
tases [38]. Thus, aberrantly expressed SYT-SSX gene prod-
ucts are likely to have primed SYT-SSX-specific CTL
precursors during the process of systemic tumor spread-
ing. Furthermore, CTLs specific for HLA-A24-positive syn-
ovial sarcoma cells were inducible from PBLs of patients
who showed increased frequency of CTL precursors in the
HLA/peptide tetramer. Together, these findings suggest
that SYT-SSX fusion gene products serve as the tumor asso-
ciated antigen of synovial sarcoma.
Antigenic peptides in bone and soft tissue sarcomas
Derivatives of fusion gene product
Identification of tumor associated antigens and related
antigenic peptides is the prerequisite for the development
of the antigen-specific peptide-based immunotherapy.
The discovery of tumor-specific chromosomal transloca-
tion and resultant fusion genes as a common event in var-
ious soft tissue sarcomas was a significant aid in antigen
identification [13-15]. Since the fusion regions of translo-
cation products are strictly limited to the corresponding
tumors [41] (Table 1), they serve as attractive targets for
tumor antigen-specific therapies. This concept has been
proven previously by the study of leukemias [42,43].
A strategic scheme for identification of therapeutic anti-
gens targeting fusion genes is shown in Fig. 1. Soft tissue
sarcomas with defined chromosomal translocation may
be subjected to search for putative antigenic sequences in
the region spanning the fusion gene. This search is based
on the recognition of anchor motifs for HLA class I allele
commonly expressed by the population affected by the
disease [44,45]. This approach is commonly referred to as
a "reverse immunology" [46,47]. In this fashion, several
antigenic peptides have been defined from SYT-SSX
[38,40,48], EWS-FLI1 [49], and PAX3-FKHR [49] fusion
gene products (Table 2).
Derivatives of lymphocyte-defined antigen
Bone and soft tissue sarcomas without known chromo-
somal translocation may be subjected to the "forward
immunology approach" [46] (Fig. 1). This approach is
based on the establishment of an autologous pair of
tumor cells and tumor cell-reactive CTLs. When the first
CTLs were expanded from patients with osteosarcoma
[26,27] and MFH [27], the expression cloning procedure
for antigen identification [11] had not yet been identified.
By using an autologous pair of osteosarcoma cell line and
CTL clone [16], we identified an antigenic peptide derived
from Papillomavirus binding factor (PBF) [17] (Table 2).
PBF was originally defined as a transcriptional regulator of
genomic DNA of the human papillomavirus type 8 [50].
The role of PBF in bone and soft tissue sarcomas still
remains uncertain. Nevertheless, PBF was found to be
expressed in 57/76 cases of bone and soft tissue sarcomas
(11/14 osteosarcomas) and 20/34 of epithelial carcino-
mas by reverse transcription polymerase chain reaction.
Immunostaining with anti-PBF antibody was positive in
45/51 bone and soft tissue sarcoma tissues (16/20
osteosarcoma), whereas it was weak and restricted in the
cytoplasm of the normal organs tested including ovary,
pancreas, and liver [17]. Although PBF could represent a
Table 1: Chromosomal translocation and fusion gene in bone and soft tissue sarcoma
Tumor Choromosomal translocation Fusion gene Frequency
Synovial sarcoma t(X;18)(p11.2;q11.2) SYT-SSX1 >60%
SYT-SSX2 35%
SYT-SSX4 rare





Alveolar rhabdomyosarcoma t(2;13)(q35;q14) PAX3-FKHR >75%
t(1;13)(q36;q14) PAX7-FKHR 10–15%
Myxoid liposarcoma t(12;16)(q13:q11) TLS-CHOP >75%
Clear cell sarcoma t(12;22)(q13;q12) EWS-ATF1 >80%
Dermatofibrosarcoma 
protuberans
t(17;22)(q22;q13) COL1A1-PDGFb >99%Journal of Translational Medicine 2005, 3:31 http://www.translational-medicine.com/content/3/1/31
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universal target for active specific immunization because
of the frequency and relative selectivity of its expression,
its utilization is limited by the rarity of the HLA allele in
association with whom its discovery occurred. The recog-
nition by the original CTL of the paired autologous tumor
cells was associated to HLA-B55. Given the low prevalence
of the HLA-B55 allele, the identified antigenic epitope is
not clinically applicable to a broad range of patients. Cur-
rently the antigenicity of other PBF-derived peptides with
high affinity for the HLA-A2 and HLA-A24 alleles, com-
mon in both the Japanese and Caucasian population, are
being evaluated for future clinical trials.
Derivatives of known tumor-associated antigen
In addition to the above described approaches aimed at
the identification of novel sarcoma antigens and related
epitopes, it is also reasonable to target known tumor-asso-
ciated antigens that had been previously identified in can-
cers other than sarcomas as long as these proteins are also
expressed by these tumors (Fig. 1). Accordingly, the
Strategies for the identification of antigenic peptides from bone and soft tissue sarcomas Figure 1
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Novel tumor antigen
Search for HLA-anchor motif
Antigenic peptide
Known tumor antigen
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expression of several cancer-testis antigens [51-54] and
other antigenic proteins over-expressed by cancers com-
pared to normal tissues [55,56] has been investigated in
bone and soft tissue sarcomas. Despite reasonable expres-
sion levels, they have not been proved to be naturally anti-
genic in patients with bone and soft tissue sarcoma and
lead to spontaneous CTL responses identifiable in the
blood of these patients. Therefore, peptides derived from
those known antigens are now being examined using
reverse immunology to test their antigenicity and binding
properties to the common HLA alleles, with the aim of
utilizing them as targets for antigen-specific
immunization.
Derivatives of SEREX-defined antigen
SEREX (serological analysis of recombinant cDNA expres-
sion library) was developed as a procedure to identify
antigens without using autologous tumor-CTL pair [57].
SEREX defines putative antigens using serum IgG antibod-
ies from cancer patients. Since isotype switching from IgM
to IgG implies the presence of specific help from CD4+ T
cells, antigens defined by SEREX are likely to contain
epitopes for CD4+ T cells. SEREX analysis has been per-
formed on patients with bone and soft tissue sarcomas
[16,58,59], displaying an array of cancer-testis antigens as
possible candidates. However, antigenic peptides have yet
to be isolated.
Clinical trials
To date, various immunotherapeutic trials have been con-
ducted in patients with bone and soft tissue sarcoma
(Table 3). They include vaccination of autologous tumors
cells [5,6,60], autologous tumor lysates [5,6], antigenic
peptide [49,61], and dendritic cells pulsed with tumor
lysate [62] or peptides [63]. Also, adoptive transfer of all-
ogeneic lymphocytes sensitized in vivo with the recipient's
tumor lysate, was reported [7,8]. None of them showed
significant adverse events resulting from vaccinations.
Immunological monitoring was not performed precisely
in these initial trials due to the lack of target specificity in
some trials and the limited expertise in immunological
monitoring at that time in which the trails were designed.
In contrast, recent trials using fusion gene-derived pep-
tides [49,61,63] associated with specific HLA alleles
revealed successful induction of tumor-specific CTLs from
five out of ten patients examined, emphasizing the immu-
nological feasibility of this approach. Notably, CTLs spe-
cific for a fusion gene-derived peptide could also be
identified in only one out of five patients before
vaccination in one of our trials [61]. Using HLA/peptide
tetrameric complexes, we also noted in this trial, that the
frequency of circulating CTL precursors specific to the
SYT-SSX peptide increased in three patients while, for
unclear reasons, decreased in one patient after vaccination
[61].
Therapeutic efficacy cannot be assessed in such explora-
tory studies including a limited number of patients. How-
ever, it is interesting to report that during the conduct of
recent clinical trials [49,60-63] tumor remission was
observed in two out of a total of 45 patients who had
received vaccination; one with Ewing's sarcoma [49] and
the other with fibrosarcoma [62]. In these trials, all
patients had advanced disease in contrast to the initial
trials that had been conducted, in adjuvant setting, in
patients with osteosarcoma [5-8]. In the latter trials, the
patients underwent definitive amputative surgery for the
primary tumor and had no detectable metastasis before
immunotherapy. The clinical efficacy of immunological
interventions was, therefore, evaluated in its ability to pre-
vent recurrence of disease which most commonly occurs
in the lungs as distant pulmonary metastases. In these
clinical trials chemotherapy was not given in combination
with immunotherapy since at that time there was no evi-
dence that chemotherapy is associated with clinical bene-
fit in adjuvant settings. Interestingly, osteosarcoma has
biological features which suite the design of adjuvant
Table 2: Antigenic peptide in bone and soft tissue sarcoma
Tumor Antigen HLA allele Peptide sequence* Reference




Ewing sarcoma EWS-FLI1 (type 1) A3, A31, B44 SSSYGQQN/PSYDSVRRGA 49
EWS-FLI1 (type 2) A2, A3, A24, B7, B44, B62 SSSYGQ/QSSLLAYNT 49
Alveolar rhabdomyosarcoma PAX3-FKHR A33, A68, B7 TIGNGLSPQ/NSIRHNLSL 49
Osteosarcoma Papillomavirus binding factor B55 CTACRWKKACQR 17
Peptide sequences shown to induce cytotoxic T lymphocites or those used in clinical trials are listed. Slash indicates the breakpoint.Journal of Translational Medicine 2005, 3:31 http://www.translational-medicine.com/content/3/1/31
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immunotherapy trials. These include the frequent exist-
ence of micrometastases on initial presentation and a ten-
dency to relapse during the first year of treatment,
especially after excision of the primary tumor [64,65]. The
disease-free survival at two years was 33% in 32 patients
who had undergone adoptive immunotherapy [8], and
44% in 16 patients vaccinated with autologous tumor
lysate [6]. In a historical control including 145 patients
treated by surgery alone, the two-year disease free survival
was as low as 22% [8], suggesting that these immuno-
therapeutic trials hold some promise. Due to their small
size and the lack of an appropriate contemporary and
matched control population the significance of these
results, however, needs to be further assessed. Neverthe-
less, the observations from these initial trials suggest that
in patients with osteosarcoma and other bone and soft tis-
sue sarcomas vaccination in adjuvant settings would be
more likely to yield clinical benefit than vaccination with
therapeutic purposes.
Conclusion
Given the rarity, relative low immunogenicity, and their
heterogeneity, bone and soft tissue sarcomas have
remained for a long time at the boundaries of tumor
immunology. Up to three decades ago, they were per-
ceived similarly by oncologists who inclined to approach
cancer with chemotherapy [66]. As chemotherapy has
relied upon intensification and multiplication of thera-
peutic schemes and the production of new chemothera-
peutics to successfully enhance its efficacy, tumor
immunologists will face the challenge of rationally
expanding the use of antigens-specific immunization to
enhance its usefulness against bone and soft tissue
sarcomas.
Abbreviations
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